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However, few subjects with a persistent serum urate less than 4.0 mg/dL were studied. Pegloticase is a recombinant uricase conjugated to polyethylene glycol approved in the US for treatment of patients with chronic refractory gout. It profoundly decreases serum uric acid in responders to <1 mg/dL. The results from the pegloticase clinical trials provided the opportunity to determine the impact of persistent and markedly low levels of serum urate on the velocity of tophus resolution. Objectives: To assess the velocity of tophus resolution in subjects treated with pegloticase for chronic refractory gout. Methods: This analysis used results from two randomized controlled trials (RCTs) of 6 months duration.
2,3 For tophus measurements, serial standardized digital photographs were analyzed by a blinded reader using computer-assisted quantitative measurement software. Subjects were defined as responders and nonresponders based upon maintenance of a serum urate <6 mg/dL during intensive monitoring periods after 3 and 6 months of treatment. Results: During the 6 months of the RCTs, a total of 952 tophus measurements were analyzed in 87 subjects, including 341 in 30 responders; 361 in 36 nonresponders receiving pegloticase infusions; and 250 in 21 subjects receiving placebo infusions. Mean serum urate levels in these subjects were 10.1, 0.3 and 0.3 mg/dL at baseline, 3 months and 6 months in responders; 10.7, 8.9 and 9.6 mg/dL in nonresponders; and 10.2, 9.8 and 9.7 mg/dL in placebo treated patients, respectively. At baseline, the mean tophus area in responders was 581.6 +/-742.7 mm 2 (mean ± SD; n=90 tophi); in nonresponders it was 676.5+/-1416.6 mm 2 (n=93 tophi); and in placebo treated subjects it was 672.9+/-1039.5 mm 2 (n=66 tophi). By regression analysis, the velocity of tophus resolution over the 6 months of treatment was 50.1 mm 2 /month in responders; 14.0 mm 2 /month in nonresponders; and 13.9 mm 2 /month in placebo treated patients (responders versus nonresponders or responders vs placebo treated subjects (p=0.001)). In responders, the mean time to total tophus resolution was estimated to be 347 days (11.5 months, with a range of 5.6-36.4 months). During the 6 month treatment period, the area under the curve (AUC) of multiple serum urate measurements in responders was 6,067.9+/-6,781.6 mg/dL hr compared with 34,647.4+/-8,586.7 and 42,451.1+/-6,396.1 mg/dL·hr in nonresponders and placebo treated subjects, respectively (p<0.001). In responders, there was a significant correlation between the velocity of tophus resolution and serum urate AUC (p=0.009). Conclusions: Pegloticase treatment causes a rapid resolution of tophi in responders as predicted from the profound and persistent serum urate lowering associated with this therapy. References: ) . Hypertriglyceridemia and dyslipidemia were significantly more frequent among L-PN patients; in other hand, frequency of tophi, STG and mean HAQ values were significantly more frequent in S-PN patients, there were no significant differences among other clinical data associated with gout itself. Background: Gouty arthritis is a common, potentially disabling and increasingly prevalent disease [1] . Last year, the European League Against Rheumatism (EULAR) task force gout updated the 2006 recommendations for the management of gout [2, 3] . The guideline stresses the application of a targeted approach when initiating urate lowering therapy (ULT) in gout patients for reaching the recommended serum urate (sUA) target values. However, data on clinical outcomes of real-world gout patients treated according to this approach are limited. Objectives: To examine the clinical outcomes achieved in two patient cohorts in which differing targeted ULT treatment approaches were employed, both aiming to reach the EULAR recommended sUA targets. Methods: We conducted a retrospective chart review study. Gout patients were included that had been treated at the rheumatology departments of two clinical centers in the Netherlands, applying different targeted ULT treatment approaches. Patients in cohort A followed an approach combining two modes of action once allopurinol monotherapy failed to reach the predefined target, whereas patients in cohort B were treated with sequential monotherapy following allopurinol
